natgillin/translations-raw huggingface dataset:
Renal insufficiency: Emtricitabine is eliminated by renal excretion and exposure to emtricitabine was significantly increased in patients with renal insufficiency (see section 5.2). 
Ledvična insuficienca: Emtricitabin se izloča preko ledvic in izpostavljenost emtricitabinu je pomembno narasla pri bolnikih z ledvično insuficienco (glejte poglavje 5.2).
The pharmacokinetics of emtricitabine are proportional to dose over the dose range of 25-200 mg following single or repeated administration. 
Farmakokinetične lastnosti emtricitabina po enkratni ali večkratni uporabi so sorazmerne odmerku, in sicer v razponu odmerka med 25 in 200 mg.
Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may lead to an increase in serum concentrations of either emtricitabine or a co-administered medicinal product due to competition for this elimination pathway. 
Sočasna uporaba emtricitabina z zdravili, ki se izločajo z aktivno tubularno sekrecijo, lahko vodi v povišanje serumskih koncentracij emtricitabina ali sočasno uporabljenih zdravil zaradi kompeticije za to pot izločanja.
Psychiatric disorders: Common: 
Psihiatrične motnje: Pogosti:
Patients with renal insufficiency can also be managed by administration of Emtriva 200 mg hard capsules at modified dose intervals. 
Bolniki z ledvično insuficienco so lahko zdravljeni tudi z Emtriva 200 mg trdimi kapsulami ob prilagojenih intervalih odmerjanja.
Patients should be instructed that any solution left in the bottle 45 days after opening should be disposed of in accordance with local requirements or returned to the pharmacy. 
6.6 Posebni varnostni ukrepi za odstranjevanje Bolniki morajo biti opozorjeni, da je treba raztopino zdravila, ki ostane v plastenki po preteku 45 dni od odprtja plastenke, zavreči v skladu z lokalnimi predpisi ali vrniti nazaj v lekarno.
What Emtriva is and what it is used for Emtriva is a treatment for Human Immunodeficiency Virus (HIV) infection in adults, children and infants aged 4 months and over. 
Kaj je zdravilo Emtriva in za kaj ga uporabljamo Zdravilo Emtriva se uporablja za zdravljenje okužbe z virusom HIV pri odraslih, otrocih in dojenčkih, starih 4 mesece ali več.
In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of hepatitis. 
Pri bolnikih z napredovalo boleznijo jeter ali cirozo se prekinitev zdravljenja ne priporoča, saj pri nekaterih bolnikih lahko povzroči poslabšanje hepatitisa.
Additionally, in a second study, treatment-experienced adults on a stable PI-based highly active antiretroviral therapy (HAART) regimen were randomised to a once daily regimen containing emtricitabine or to continue with their PI-HAART regimen. 
V drugi študiji se je pri odraslih, ki se zdravijo dalj časa s PI osnovanim visoko aktivnim stabilnim protiretrovirusnim režimom zdravljenja (HAART, highly active antiretroviral therapy), v nadaljevanju naključno porazdeljeno uporabilo ali kombinirano protiretrovirusno zdravljenje z emtricitabinom ali pa so nadaljevali s PI-HAART režimom.
Emtriva is also available as an oral solution for use in children and infants aged 4 months and over, patients who have difficulty in swallowing and patients with kidney problems. 
Zdravilo Emtriva je na razpolago tudi v obliki peroralne raztopine, predvsem za uporabo pri otrocih in dojenčkih starih 4 mesece ali več, bolnikih, ki težko požirajo in bolnikih, ki imajo ledvične težave.
Emtricitabine in combination with other antiretroviral agents, including nucleoside analogues, non-nucleoside analogues and PIs, has been shown to be effective in the treatment of HIV infection in treatment-naïve patients and treatment-experienced patients with stable virological control. 
Emtricitabin, v kombinaciji z drugimi protiretrovirusnimi učinkovinami, vključno z analogi nukleozidov in učinkovinami, ki niso analogi nukleozidov ter PI, se je izkazal za učinkovito zdravilo pri zdravljenju okužbe z virusom HIV pri bolnikih, ki se zdravijo prvič in pri bolnikih, ki se zdravijo že dalj časa in imajo stabilno stanje virusa v telesu.
Plasma emtricitabine exposure (AUC) in infants up to 3 months of age who received 3 mg/kg emtricitabine once daily was similar to that observed using 6 mg/kg daily doses in HIV infected adults and children aged 4 months and over. 
Plazemska izpostavljenost emtricitabinu (AUC) pri dojenčkih, starih do 3 mesece, ki so prejemali 3 mg/kg emtricitabina enkrat dnevno, je bila podobna tisti, ki so jo opazili pri odraslih in otrocih, starih 4 mesece ali več, okuženih z virusom HIV, ki so prejemali dnevne odmerke 6 mg/kg.
Emtricitabine did not inhibit in vitro drug metabolism mediated by the following human CYP450 isoenzymes: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 and 3A4. 
Emtricitabin ni inhibiral in vitro presnove zdravil s pomočjo kateregakoli od naslednjih humanih CYP450 izoencimov: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 in 3A4.
In patients with ESRD on haemodialysis, approximately 30% of the emtricitabine dose was recovered in dialysate over a 3 hour dialysis period which had been started within 1.5 hours of emtricitabine dosing (blood flow rate of 400 mL/min and dialysate flow rate of approximately 600 mL/min). 
Pri bolnikih z ledvičnim obolenjem v zadnji fazi (ESRD, end-stage renal disease) na hemodializi je bilo približno 30 % odmerka emtricitabina pridobljenega v dializatu po 3 urah dialize, s katero je bolnik začel v roku 1,5 ure po uporabi emtricitabina (pretok krvi je 400 ml/min in pretok dializata je približno 600 ml/min).
If a patient misses a dose of Emtriva within 12 hours of the time it is usually taken, the patient should take Emtriva with or without food as soon as possible and resume their normal dosing schedule. 
Če bolnik izpusti odmerek zdravila Emtriva v roku 12 ur od časa, ko ga običajno vzame, naj bolnik vzame zdravilo Emtriva s hrano ali brez takoj, ko je mogoče, nato pa nadaljuje s svojim običajnim režimom odmerjanja.
When tested for activity against laboratory strains of HBV, the IC50 value for emtricitabine was in the range of 0.01 to 0.04 µmol/l. 
Pri testih aktivnosti proti laboratorijskim sevom HBV je bila vrednost IC50 za emtricitabin v razponu od 0,01 do 0,04 µmol/l.
If it's less than an hour since you took Emtriva, take another dose. 
Če je manj kot ena ura odkar ste vzeli zdravilo Emtriva, vzemite še en odmerek.
The pack also contains a 30 mL polypropylene measuring cup with 1.0 mL graduations. 
Pakiranje vsebuje še 30 ml polipropilensko merico z 1,0 ml skalo.
vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discolouration (increased pigmentation)1,2 
vezikulobulozni izpuščaj, pustulozni izpuščaj, makulopapulozni izpuščaj, rdečica, pruritus, koprivnica, sprememba obarvanosti kože (povečana pigmentacija)1,2
This medicinal product contains 36 mg of sodium per 24 mL, equivalent to 1.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult. 
To zdravilo vsebuje 36 mg natrija na 24 ml, kar ustreza 1,8 % največjega dnevnega vnosa s hrano, ki ga priporoča Svetovna zdravstvena organizacija (WHO), in znaša 2 g natrija za odraslega.
Adults: The recommended dose of Emtriva is one 200 mg hard capsule, taken orally, once daily. 
Odrasli: Priporočeni odmerek zdravila Emtriva je ena 200 mg trda kapsula, peroralno, enkrat dnevno.
If you notice signs of inflammation or infection soon after you start taking Emtriva, 
Če opazite simptome vnetja ali okužbe kmalu po začetku jemanja zdravila Emtriva, o tem nemudoma obvestite zdravnika.
Emtricitabine is principally eliminated by the kidney via glomerular filtration and active tubular secretion. 
Emtricitabin se v glavnem izloča s pomočjo ledvic preko glomerularne filtracije in aktivne tubularne sekrecije.
• The other ingredients are: cotton candy flavouring, disodium edetate, hydrochloric acid, methyl parahydroxybenzoate (E218), propylene glycol, propyl parahydroxybenzoate (E216), sodium hydroxide, sodium phosphate monobasic hydrate, sunset yellow (E110), purified water, xylitol (E967). 
• Druge sestavine zdravila so: aroma sladkorne pene (Cotton candy flavouring), dinatrijev edetat, klorovodikova kislina, metilparahidroksibenzoat (E218), propilenglikol, propilparahidroksibenzoat (E216), natrijev hidroksid, natrijev dihidrogenfosfat hidrat, oranžno FCF (E110), prečiščena voda, ksilitol (E967).
There was no evidence of toxicity to mitochondria in vitro or in vivo. 
Toksičnost za mitohondrije pri in vitro ali in vivo pogojih ni bila dokazana.
Emtriva comes in bottles or blister packs containing 30 capsules. 
Zdravilo Emtriva je na voljo v plastenkah ali v pretisnih omotih, ki vsebujejo 30 kapsul.
While taking Emtriva you may still develop infections or other illnesses associated with HIV infection. 
V času uporabe zdravila Emtriva se lahko okužite ali zbolite za boleznimi, ki so povezane z okužbo z virusom HIV.
Elderly patients are more likely to have decreased renal function, therefore caution should be exercised when treating elderly patients with Emtriva (see section 4.2). 
Verjetnost, da je ledvična funkcija pri starejših bolnikih zmanjšana, je večja, zato je pri zdravljenju starejših bolnikov z zdravilom Emtriva potrebna previdnost (glejte poglavje 4.2).
Mechanism of action and pharmacodynamic effects Emtricitabine is a synthetic nucleoside analogue of cytidine with activity that is specific to HIV-1, HIV-2 and HBV. 
Mehanizem delovanja in farmakodinamski učinki Emtricitabin je sintetični nukleozidni analog citidina z učinkovanjem, ki je specifično HIV-1, HIV-2
Paediatric population: The recommended dose of Emtriva 10 mg/mL oral solution is 6 mg/kg up to a maximum of 240 mg (24 mL) once daily. 
Pediatrična populacija: Priporočeni odmerek peroralne raztopine Emtriva 10 mg/ml je 6 mg/kg do maksimalno 240 mg (24 ml) enkrat dnevno.
Animal studies do not indicate reproductive toxicity. 
Študije na živalih ne kažejo na vpliv na sposobnost razmnoževanja.
The mean AUC in 77 infants, children and adolescents receiving 6 mg/kg emtricitabine once daily as oral solution or 200 mg emtricitabine as hard capsules once daily was similar to the mean AUC of 10.0 µg·h/mL in 20 adults receiving 200 mg hard capsules once daily. 
Povprečna vrednost AUC pri 77 dojenčkih, otrocih in mladostnikih, ki so dobivali 6 mg/kg emtricitabina v obliki peroralne raztopine enkrat dnevno ali 200 mg emtricitabina v obliki trdih kapsul enkrat dnevno je bila podobna povprečni vrednosti AUC 10,0 µg·h/ml pri 20 odraslih, ki so dobivali
Therefore, clinical response to treatment and renal function should be closely monitored in patients treated with a reduced dose of emtricitabine (see sections 4.2 and 5.2). 
Zato je potrebno pozorno nadzorovati klinični odziv na zdravljenje in ledvično funkcijo pri bolnikih, ki se zdravijo z zmanjšanim odmerkom emtricitabina (glejte poglavji 4.2 in 5.2).
In 20 HIV infected subjects receiving 200 mg emtricitabine daily as hard capsules, steady-state plasma emtricitabine peak concentrations (Cmax), trough concentrations (Cmin) and area under the plasma concentration time curve over a 24-hour dosing interval (AUC) were 1.8 ± 0.7 µg/mL, 0.09 ± 0.07 µg/mL and 10.0 ± 3.1 µg·h/mL, respectively. 
Pri 20 bolnikih z okužbo z virusom HIV, ki so prejemali 200 mg emtricitabina dnevno v obliki trdih kapsul, so bile koncentracije dinamičnega ravnovesja plazemskega emtricitabina sledeče: najvišja (Cmax) 1,8 ± 0,7 µg/ml, najnižja (Cmin) 0,09 ± 0,07 µg/ml in površina pod časovno krivuljo plazemske koncentracije v 24-urnem dozirnem intervalu (AUC), 10,0 ± 3,1 µg·h/ml.
The following side effects are very common (these can affect at least 10 in every 100 patients): 
Naslednji neželeni učinki so zelo pogosti (pojavijo se lahko pri najmanj 10 od 100 bolnikov):
Recommended dose of Emtriva 10 mg/mL oral solution every 24 hours 
Priporočeni odmerek Emtriva 10 mg/ml peroralne raztopine vsakih 24 ur
How to store Emtriva 
Kako jemati zdravilo Emtriva
One 200 mg hard capsule every 96 hours 
Ena 200 mg trda kapsula vsakih 96 ur
In virologically stable treatment-experienced adults, emtricitabine, in combination with an NRTI (either stavudine or zidovudine) and a PI or an NNRTI was shown to be non-inferior to lamivudine with respect to the proportion of responders (< 400 copies/mL) through 48 weeks (77% emtricitabine, 82% lamivudine). 
Pri virološko stabilnih odraslih, ki se zdravijo že dalj časa, se emtricitabin, v kombinaciji z NRTI (ali stavudinom ali zidovudinom) in PI ali NNRTI, ni obnesel slabše od lamivudina glede na delež odzivov (< 400 virionov/ml) v obdobju 48 tednov (77 % emtricitabin, 82 % lamivudin).
Adults: The recommended dose of Emtriva 10 mg/mL oral solution is 240 mg (24 mL) once daily. 
Odrasli: Priporočeni odmerek Emtriva 10 mg/ml peroralne raztopine je 240 mg (24 ml) enkrat dnevno.
• rashes (including red spots or blotches sometimes with blistering and swelling of the skin), 
• izpuščaji (vključno z rdečimi pikami ali ogrci, včasih z mehurjasto in oteklo kožo), kar je lahko alergična reakcija, srbečica, sprememba obarvanosti kože, vključujoč temne lise
Subjects were grouped according to baseline creatinine clearance (> 80 mL/min as normal function; 50-80 mL/min as mild impairment; 30-49 mL/min as moderate impairment; < 30 mL/min as severe impairment; < 15 mL/min as functionally anephric requiring haemodialysis). 
Osebe so bile razdeljene v skupine glede na osnovni očistek kreatinina (> 80 ml/min kot normalna funkcija; 50-80 ml/min kot blaga oslabelost; 30-49 ml/min kot zmerna oslabelost;
Children aged 4 months and over, who weigh at least 33 kg may either take one 200 mg hard capsule daily or may take emtricitabine as the oral solution up to a maximum of 240 mg once daily. 
Otroci, stari 4 mesece ali več, ki tehtajo vsaj 33 kg lahko vzamejo ali eno 200 mg trdo kapsulo dnevno ali emtricitabin v obliki peroralne raztopine do maksimalno 240 mg enkrat dnevno.
Table 1 below provides dose interval adjustment guidelines for the 200 mg hard capsules according to the degree of renal insufficiency. 
Spodnja preglednica 1 prikazuje smernice prilagoditve intervala odmerjanja za 200 mg trde kapsule glede na stopnjo ledvične insuficience.
You do not need to take another capsule if you were sick more than an hour after taking Emtriva. 
Še ene kapsule vam ni treba vzeti, če je bruhanje nastopilo več kot eno uro po zaužitju zdravila Emtriva.
There is no experience of the use of Emtriva in patients who are failing their current regimen or who have failed multiple regimens (see section 5.1). 
Z uporabo zdravila Emtriva pri bolnikih, pri katerih dotedanji ali večkratni režim zdravljenja ni bil uspešen ni izkušenj (glejte poglavje 5.1).
Therefore, clinical response to treatment and renal function should be closely monitored in these patients (see section 4.4). 
Zaradi tega je potrebno pri teh bolnikih pozorno spremljati klinični odziv na zdravljenje in ledvično funkcijo (glejte poglavje 4.4).
One mL of Emtriva oral solution contains 10 mg of emtricitabine (10 mg/mL). 
En mililiter peroralne raztopine Emtriva vsebuje 10 mg emtricitabina (10 mg/ml).
Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose. 
Po peroralni uporabi emtricitabina se le-ta hitro in znatno absorbira in doseže najvišjo koncentracijo v plazmi v 1-2 urah.
If you would like to switch from taking Emtriva oral solution to Emtriva hard capsules, please talk to your doctor. 
Če bi namesto peroralne raztopine Emtriva raje uporabljali trde kapsule Emtriva, se posvetujte s svojim zdravnikom.
Emtriva oral solution is a clear, orange to dark orange solution that comes in bottles containing 170 mL with a measuring cup. 
Peroralna raztopina Emtriva je prozorna tekočina, oranžne do temno oranžne barve, na voljo v 170 ml plastenki skupaj z merico.
This indication is based on studies in treatment-naïve patients and treatment-experienced patients with stable virological control. 
Indikacija temelji na študijah bolnikov, ki se zdravijo prvič in bolnikov, ki se zdravijo že dalj časa ter imajo stabilno stanje virusa v telesu.
Non-clinical data on emtricitabine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction and development. 
5.3 Predklinični podatki o varnosti Predklinični podatki o emtricitabinu na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja in razvoja ne kažejo posebnega tveganja za človeka.
Emtriva 200 mg hard capsules may be taken with or without food. 
Emtriva 200 mg trde kapsule se lahko uporablja s hrano ali brez.
Discontinuation of Emtriva therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis (see section 4.4). 
Prekinitev zdravljenja z zdravilom Emtriva pri bolnikih s hkratno HIV in HBV okužbo je lahko povezana s hudimi akutnimi poslabšanji hepatitisa (glejte poglavje 4.4).
Caution should be exercised when emtricitabine is co-administered with medicinal products that are eliminated by active tubular secretion as such co-administration may lead to an increase in serum concentrations of either emtricitabine or a co-administered medicinal product, due to competition for this elimination pathway (see section 4.5). 
Posebno pozornost zahteva sočasna uporaba emtricitabina in zdravil, ki se izločajo iz telesa z aktivno tubularno sekrecijo, ker lahko takšna sočasna uporaba, zaradi kompeticije za to pot izločanja, vodi k povišanju serumskih koncentracij bodisi emtricitabina bodisi sočasno uporabljenega zdravila (glejte poglavje 4.5).
Nervous system disorders: Very common: 
Bolezni živčevja: Zelo pogosti:
In infants and children older than 4 months, the majority of patients achieved or maintained complete suppression of plasma HIV-1 RNA through 48 weeks (89% achieved ≤ 400 copies/mL and 77% achieved ≤ 50 copies/mL). 
Pri dojenčkih in otrocih starejših od 4 mesecev je večina v 48. tednih dosegla ali ohranila popolno supresijo plazemske HIV-1 RNA (89 % je doseglo ≤ 400 virionov/ml in 77 % je doseglo
Use the measuring cup provided in the carton to measure the correct dose. 
Pri odmeri pravilnega odmerka si pomagajte z merico, ki je priložena v škatli.
Please refer to the Summary of Product Characteristics for Emtriva 200 mg hard capsules. 
Prosimo, upoštevajte povzetek glavnih značilnosti Emtriva 200 mg trdih kapsul.
Table 1: Dose interval guidelines for 200 mg hard capsules adjusted according to creatinine clearance 
Preglednica 1: Smernice intervala odmerjanja 200 mg trdih kapsul, prilagojene očistku kreatinina
Patients with chronic hepatitis B or C infection treated with CART are at increased risk of experiencing severe, and potentially fatal, hepatic adverse events. 
Pri bolnikih s kronično okužbo s hepatitisom B ali C, ki se zdravijo s CART, je povečana možnost resnega in potencialno usodnega neželenega delovanja jeter.
If the patient vomits within 1 hour of taking Emtriva, another dose should be taken. 
Če bolnik v roku 1 ure od jemanja zdravila Emtriva bruha, naj vzame drugi odmerek.
Emtriva oral solution contains sunset yellow (E110) which may cause allergic reactions, methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). 
Emtriva peroralna raztopina vsebuje oranžno FCF (E110), ki lahko povzroči alergijske reakcije, metilparahidroksibenzoat (E218) in propilparahidroksibenzoat (E216), ki tudi lahko povzročita alergijske rekacije (lahko zapoznele).
elevated amylase including elevated pancreatic amylase, elevated serum lipase, vomiting, abdominal pain, dyspepsia Hepatobiliary disorders: Common: 
zvišana amilaza vključno z zvišano pankreasno amilazo, povišanje serumske lipaze, bruhanje, bolečine v trebuhu, dispepsija Bolezni jeter, žolčnika in žolčevodov: Pogosti:
Each hard capsule contains 200 mg of emtricitabine. 
Vsaka trda kapsula vsebuje 200 mg emtricitabina.
• If you have both HIV infection and hepatitis B, it is especially important not to stop your 
• Če ste okuženi hkrati z virusom HIV in hepatitisom B, je še zlasti pomembno, da ne prenehate z zdravljenjem z zdravilom Emtriva, ne da bi se prej posvetovali s svojim zdravnikom.
The following side effects are uncommon (these can affect up to 1 in every 100 patients): 
Naslednji neželeni učinki so občasni (pojavijo se lahko pri največ 1 od 100 bolnikov):
If Emtriva is discontinued in patients co-infected with HIV and hepatitis B virus (HBV), these patients should be closely monitored for evidence of exacerbation of hepatitis (see section 4.4). 
Če se jemanje zdravila Emtriva prekine pri bolnikih s hkratno okužbo s HIV in z virusom hepatitisa B (HBV), je treba pri teh bolnikih skrbno nadzorovati znake poslabšanja hepatitisa (glejte poglavje 4.4).
Pack size: 30 hard capsules. 
Velikost pakiranja: 30 trdih kapsul.
Emtricitabine is not recommended as monotherapy for the treatment of HIV infection. 
Emtricitabin se ne priporoča za samostojno terapijo pri zdravljenju okužbe z virusom HIV.
Emtriva oral solution can be taken with or without food. 
Peroralno raztopino Emtriva lahko jemljete z ali brez hrane.
Emtriva contains the active substance emtricitabine. 
Zdravilo Emtriva vsebuje zdravilno učinkovino emtricitabin.
Emtricitabine did not inhibit the enzyme responsible for glucuronidation. 
Emtricitabin ni inhibiral delovanja encima za glukuronidacijo.
Exacerbations of hepatitis after discontinuation of treatment: In HIV infected patients co-infected with HBV, exacerbations of hepatitis may occur after discontinuation of treatment (see section 4.4). 
Eksacerbacije hepatitisa po prekinitvi zdravljenja: Pri bolnikih, okuženih s HIV, ki so hkrati okuženi s HBV, se lahko po prekinitvi zdravljenja pokažejo znaki eksacerbacije hepatitisa (glejte poglavje 4.4).
elevated serum aspartate aminotransferase (AST) and/or elevated serum ALT, hyperbilirubinaemia Skin and subcutaneous tissue disorders: Common: 
povišanje serumske aspartat-aminotransferaze (AST) in/ali povišanje serumske ALT, hiperbilirubinemija Bolezni kože in podkožja: Pogosti:
Recommended dose interval for 200 mg hard capsules 
Pripročen interval odmerjanja za 200 mg trde kapsule
Table 1: Daily doses of Emtriva 10 mg/mL oral solution adjusted according to creatinine clearance 
Preglednica 1: Dnevni odmerki Emtriva 10 mg/ml peroralne raztopine prilagojeni očistku kreatinina
If overdose occurs, the patient should be monitored for signs of toxicity and standard supportive treatment applied as necessary. 
Pri bolniku, ki je prejel prevelik odmerek zdravila, je potrebno biti pozoren na znake zastrupitve in če je potrebno, pričeti z osnovnim podpornim zdravljenjem zastrupitve.
There is insufficient information on the effects of emtricitabine in newborns/infants. 
Dojenje Pokazalo se je, da se emtricitabin izloča v materino mleko Podatki o učinku emtricitabina na dojene novorojence/otroke so nezadostni.
Consequently, either a dose interval adjustment (using Emtriva 200 mg hard capsules) or a reduction in the daily dose of emtricitabine (using Emtriva 10 mg/mL oral solution) is required in all patients with creatinine clearance < 30 mL/min. 
Posledično je pri vseh bolnikih z očistkom kreatinina < 30 ml/min potrebna ali prilagoditev intervala odmerjanja (pri uporabi Emtriva 200 mg trdih kapsul) ali znižanje dnevnega odmerka emtricitabina (pri uporabi Emtriva 10 mg/ml peroralne raztopine).
Table 1 below provides daily doses of Emtriva 10 mg/mL oral solution according to the degree of renal insufficiency. 
Spodnja preglednica 1 prikazuje dnevne odmerke Emtriva 10 mg/ml peroralne raztopine glede na stopnjo ledvične insuficience.
Please refer to the Summary of Product Characteristics for Emtriva 10 mg/mL oral solution. 
Prosimo, upoštevajte povzetek glavnih značilnosti Emtriva 10 mg/ml peroralne raztopine.
The content of the bottle should be used up within 45 days of opening. 
Po odprtju plastenke morate raztopino uporabiti v roku 45 dni.
Amber-coloured polyethylene terephthalate (PET) bottle with a child-resistant closure. 
Rumeno rjava polietilenska tereftalatska (PET) plastenka z za otroke varno zaporko.